NL8702853A - Farmaceutische samenstellingen. - Google Patents

Farmaceutische samenstellingen. Download PDF

Info

Publication number
NL8702853A
NL8702853A NL8702853A NL8702853A NL8702853A NL 8702853 A NL8702853 A NL 8702853A NL 8702853 A NL8702853 A NL 8702853A NL 8702853 A NL8702853 A NL 8702853A NL 8702853 A NL8702853 A NL 8702853A
Authority
NL
Netherlands
Prior art keywords
sub
methyl
pharmaceutical composition
physiologically acceptable
composition according
Prior art date
Application number
NL8702853A
Other languages
English (en)
Dutch (nl)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40347948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL8702853(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NL8702853A publication Critical patent/NL8702853A/nl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
NL8702853A 1985-06-25 1987-11-27 Farmaceutische samenstellingen. NL8702853A (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8516083 1985-06-25
GB858516083A GB8516083D0 (en) 1985-06-25 1985-06-25 Heterocyclic compounds
GB868628474A GB8628474D0 (en) 1985-06-25 1986-11-28 Pharmaceutical compositions
GB8628474 1986-11-28

Publications (1)

Publication Number Publication Date
NL8702853A true NL8702853A (nl) 1988-06-16

Family

ID=40347948

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8702853A NL8702853A (nl) 1985-06-25 1987-11-27 Farmaceutische samenstellingen.

Country Status (22)

Country Link
US (2) US4753789A (fr)
EP (2) EP0431443A3 (fr)
JP (2) JPS6253920A (fr)
AT (2) ATE134510T1 (fr)
AU (2) AU609028B2 (fr)
BE (1) BE1002249A4 (fr)
CA (1) CA1296637C (fr)
CH (1) CH672068A5 (fr)
CY (1) CY2000A (fr)
DE (2) DE3650488T2 (fr)
DK (1) DK624687A (fr)
FR (1) FR2613934B1 (fr)
GB (3) GB8516083D0 (fr)
HK (1) HK82597A (fr)
IE (1) IE60908B1 (fr)
IL (1) IL84638A (fr)
IT (1) IT1211937B (fr)
NL (1) NL8702853A (fr)
NZ (1) NZ222743A (fr)
SE (1) SE8704747L (fr)
SG (1) SG43311A1 (fr)
ZA (1) ZA878927B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0405617A3 (en) * 1985-03-14 1992-11-25 Beecham Group P.L.C. Medicaments for the treatment of anxiety
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
GB8627909D0 (en) * 1986-11-21 1986-12-31 Glaxo Group Ltd Medicaments
US5330982A (en) * 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
AU618520B2 (en) * 1986-12-17 1992-01-02 Glaxo Group Limited Medicaments
GB8630080D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
GB8630079D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
JPH0754759B2 (ja) * 1987-04-27 1995-06-07 日本電信電話株式会社 プラズマ処理方法および装置並びにプラズマ処理装置用モード変換器
US4943428A (en) * 1987-07-10 1990-07-24 Wright State University Stimulation of serotonin-1A receptors in mammals to alleviate motion sickness and emesis induced by chemical agents
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
GB8816187D0 (en) * 1988-07-07 1988-08-10 Glaxo Group Ltd Medicaments
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
AU627221B2 (en) * 1988-09-27 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Pyridoindole derivatives and processes for preparation thereof
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5039528A (en) * 1989-12-11 1991-08-13 Olney John W EAA antagonists as anti-emetic drugs
US4971651A (en) * 1990-02-05 1990-11-20 Hitachi, Ltd. Microwave plasma processing method and apparatus
JPH06509073A (ja) * 1991-06-26 1994-10-13 セプラコア,インコーポレーテッド 光学的に純粋なs(−)オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
CA2112487C (fr) * 1991-06-26 2003-04-15 James W. Young Methode et compositions pour le traitement des vomissements, des nausees et d'autres troubles a l'ondansetron optiquement pur r(+)
EP1082959A1 (fr) * 1991-09-20 2001-03-14 Glaxo Group Limited Utilisation des NK1-antagonistes pour le traitement de la depression
EP0688216A1 (fr) * 1993-03-08 1995-12-27 Fujisawa Pharmaceutical Co., Ltd. Utilisation nouvelle d'un compose presentant un antagonisme 5-ht
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
JP2002538102A (ja) 1999-03-01 2002-11-12 セプラコア インコーポレーテッド 光学的に純粋なr(+)オンダンセトロンを使用する無呼吸および無呼吸障害の治療方法
KR100434390B1 (ko) * 2001-04-20 2004-06-04 안국약품 주식회사 1,2,3,9-테트라히드로-9-메틸-3-[(2-메틸-1h-이미다졸-1-일)메틸]-4h-카바졸-4-온을 유효성분으로 하는 비강분무용조성물
DE10393729T5 (de) * 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
US20040147510A1 (en) * 2003-01-13 2004-07-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7288660B2 (en) * 2004-05-07 2007-10-30 Taro Pharmaceutical Industries Limited Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
WO2008049552A1 (fr) * 2006-10-24 2008-05-02 Helsinn Healthcare S.A. Capsules molles comprenant du chlorhydrate de palonosétron ayant une stabilité et une biodisponibilité améliorées
JP2010050046A (ja) 2008-08-25 2010-03-04 Hitachi High-Technologies Corp プラズマ処理装置
EP2519226A1 (fr) 2009-12-28 2012-11-07 MonoSol Rx, LLC Formes pharmaceutiques se présentant sous la forme de films administrables par voie orale contenant de l'ondansétron
MX342993B (es) 2013-04-25 2016-10-13 Inst Mexicano Del Petróleo Proceso de obtencion de copolimeros aleatorios derivados del acido itaconico y/o sus isomeros y alquenil sulfonatos de sodio y uso del producto obtenido.
WO2018129434A1 (fr) 2017-01-09 2018-07-12 Gt Biopharma, Inc. Utilisation et composition pour traiter la myasthénie grave et d'autres syndromes myasthéniques

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040489A1 (fr) * 1980-05-17 1981-11-25 FISONS plc Mélanges, sels, emballages et compositions pharmaceutiques contenant l'acide 5-(2-hydroxypropoxy)-4-oxo-8-propyl-4H-1-benzopyrane-2-carboxylique ou un de ses dérivés et une antihistamine antagoniste des récepteurs H2
BE894285A (fr) * 1981-09-04 1983-03-02 Glaxo Group Ltd Composition pharmaceutique contenant un medicament anti-inflammatoire et de la ranitidine ou un sel de ce compose
FR2557110B1 (fr) * 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
FR2561244B1 (fr) * 1984-01-25 1988-03-04 Glaxo Group Ltd Composes heterocycliques du type tetrahydrocarbazolone, procede pour leur preparation et composition pharmaceutique les comprenant
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
EP0191562B1 (fr) * 1985-01-23 1991-07-10 Glaxo Group Limited Dérivés de tétrahydrocarbazolones
EP0405617A3 (en) * 1985-03-14 1992-11-25 Beecham Group P.L.C. Medicaments for the treatment of anxiety
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8630079D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
SE8704747D0 (sv) 1987-11-27
CH672068A5 (fr) 1989-10-31
EP0226266A2 (fr) 1987-06-24
ATE134510T1 (de) 1996-03-15
FR2613934A1 (fr) 1988-10-21
GB8727836D0 (en) 1987-12-31
GB8516083D0 (en) 1985-07-31
DK624687D0 (da) 1987-11-27
JPS63198623A (ja) 1988-08-17
SG43311A1 (en) 1997-10-17
US4753789A (en) 1988-06-28
IT1211937B (it) 1989-11-08
CY2000A (en) 1997-12-05
ZA878927B (en) 1988-10-26
EP0226266A3 (en) 1990-01-24
EP0431443A2 (fr) 1991-06-12
US4929632A (en) 1990-05-29
DE3650488D1 (de) 1996-04-04
DK624687A (da) 1988-05-29
ATA312587A (de) 1992-05-15
AU6703786A (en) 1988-06-30
SE8704747L (sv) 1988-05-29
AU8191487A (en) 1988-06-02
IE873230L (en) 1988-05-28
HK82597A (en) 1997-06-27
GB2200046B (en) 1990-09-26
EP0226266B1 (fr) 1996-02-28
EP0431443A3 (en) 1991-09-18
AU616386B2 (en) 1991-10-31
GB2200046A (en) 1988-07-27
JPH0324447B2 (fr) 1991-04-03
FR2613934B1 (fr) 1993-07-09
IE60908B1 (en) 1994-08-24
JPS6253920A (ja) 1987-03-09
AT395374B (de) 1992-12-10
NZ222743A (en) 1991-09-25
CA1296637C (fr) 1992-03-03
IL84638A (en) 1992-05-25
IT8748643A0 (it) 1987-11-27
BE1002249A4 (fr) 1990-11-06
DE3650488T2 (de) 1996-09-05
AU609028B2 (en) 1991-04-26
GB8628474D0 (en) 1987-01-07
DE3740351A1 (de) 1988-06-09

Similar Documents

Publication Publication Date Title
NL8702853A (nl) Farmaceutische samenstellingen.
US4835173A (en) Method of medical treatment
JPS63253083A (ja) 医薬
JPS623812B2 (fr)
US4983621A (en) Medicaments
US6544550B1 (en) Medicaments for gastrointestinal disorders
JP2834175B2 (ja) 医 薬
AU666904B2 (en) Medical use for atypical beta-adrenoceptor agonists
JPS63211227A (ja) 医薬
IL95245A (en) Pharmaceutical preparations containing 1,2,3,9, - tetrahydro-9-methyl-3-] 2-methyl-H1-imidazol-1-yl (methyl [-H4- carbazole-4-carbazol-4-one for the treatment of bulimia and
NL8802906A (nl) Geneesmiddel.
JPH07503240A (ja) 3‐アリールインドールおよび1‐アリールインダゾール誘導体の精神病の治療のための使用

Legal Events

Date Code Title Description
BV The patent application has lapsed